• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,328.19 -516.33
( -0.66%)
Global Indices
Nasdaq
49,619.91 1.93
(0.00%)
Dow Jones
7,417.79 59.68
(0.81%)
Hang Seng
62,681.30 -152.54
(-0.24%)
Nikkei 225
10,228.01 -48.94
(-0.48%)
Forex
USD-INR
94.67 -0.51
(-0.53%)
EUR-INR
111.19 -0.10
(-0.09%)
GBP-INR
128.70 -0.19
(-0.14%)
JPY-INR
0.60 0.00
(0.12%)

EQUITY - MARKET SCREENER

Industry :  
BSE Code
ISIN Demat
Book Value()
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
EPS(TTM)
Face Value()
Div & Yield %
 

mega corporation ltd
Aarti Drugs gains as arm incorporates step-down subsidiary in Chile
Mar 04,2026
With this incorporation, Tripharma Chile SpA becomes a step-down subsidiary of Aarti Drugs. The newly formed entity has been established to market formulation drugs and participate in government tenders as well as the private pharmaceutical market in Chile. The business activities of the new subsidiary are aligned with those of its holding companies.

The cost of subscription stands at 1,000,000 Chilean pesos towards share capital contribution, comprising 1,000,000 shares. The entire share capital of Tripharma Chile SpA will be held by Pinnacle Chile SpA, making it a wholly owned step-down subsidiary of the company.

Aarti Drugs was established in the year 1984 and forms part of the $6 billion Aarti Group of Industries. The company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates and speciality chemicals and produces formulations with its wholly-owned subsidiary, Pinnacle Life Science.

The company reported a 9.4% increase in consolidated net profit to Rs 40.54 crore on an 8.1% rise in net sales to Rs 601.71 crore in Q3 FY26 as compared with Q3 FY25.